KPV FDA Status: The Vote, and What It Was Actually For

Current status: KPV is not FDA-approved, is not on the 503A bulk drug substances list, and cannot legally be compounded in the US today. On July 23, 2026 an FDA advisory committee recommended adding it — non-bindingly, narrowly, and against the advice of the agency's own scientific reviewers.

The vote

At the July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee (PCAC), KPV free base and KPV acetate were voted on separately for inclusion on the section 503A bulks list. Both cleared 8–6 in favor with one abstention¹².

FDA has not published minutes; those tallies are reported by trade and news outlets that covered the meeting, and we cite them as such.

The indication FDA actually reviewed: wound healing and inflammatory conditions

FDA published the specific use it evaluated for each substance ahead of the meeting. For KPV free base and KPV acetate it was wound healing and inflammatory conditions³.

Of the seven substances on the agenda, KPV's reviewed indication is the closest to how it is actually marketed — but "inflammatory conditions" in the FDA's sense means the gut and skin inflammation literature, not sports inflammation. KPV is a tripeptide, the C-terminal fragment of α-melanocyte-stimulating hormone, and its most developed published work sits in models of intestinal inflammation and colitis⁴⁵, which we cover in KPV: the anti-inflammatory peptide, reviewed.

Athletic recovery, tendon or ligament healing, post-exercise inflammation, and performance were not evaluated and were not voted on. If you arrived here from a vendor pitching KPV for training recovery, the vote you are reading about did not examine that use.

The objection that defined the meeting

FDA scientists recommended against all seven peptides on the agenda, citing missing human data and safety concerns⁶. The most striking moment for KPV came from the committee itself. Josh Mailman, a panel member and president of a research foundation board, said during the KPV discussion: "I'm voting on something here, but I don't know what that something is. It's kind of like a black box to me." He voted no².

Another no vote, from anesthesiologist Dr. Elizabeth Rebello of MD Anderson, put the broader concern this way: "I'm concerned that we are responding to market induced demand rather than a decision based in solid science"⁶.

They lost. Eight new members had been appointed to the committee shortly before the meeting, most with ties to the peptide industry, and NBC News reported that all eight voted yes on KPV — six members voted no, one abstained². That is the entire margin.

What still has to happen

A favorable advisory vote lists nothing. To place KPV on 21 CFR 216.23, FDA must publish a proposed rule, take public comment, and issue a final rule⁷. Only the final rule changes the list, which today contains six substances and no peptide⁷.

The single completed precedent for this rulemaking took roughly three years — proposed rule December 2016, final rule effective March 21, 2019⁸. FDA has published no timeline for this round. The widely repeated "proposed rule in 9 to 18 months" figure appears on vendor and affiliate blogs and has no FDA source.

What you should not conclude

• •Not that KPV is FDA approved or endorsed. 21 CFR 216.23(d) states that representing a compounded drug made from a listed bulk substance as "FDA approved, or otherwise endorsed by FDA generally or for a particular indication" causes it to be misbranded under sections 502(a) and/or 502(bb) of the Act⁷. That applies to substances that have already completed rulemaking.
• •Not that oral or topical KPV products are now cleared. Nothing about the vote touches supplements, "research use only" vials, or compounded products that do not exist yet.
• •Not that the human evidence improved. No new trial was published; a committee voted. KPV's published record remains largely preclinical, dominated by rodent colitis models and nanoparticle delivery work⁴⁵.
• •Not that anything is different for tested athletes. KPV has no marketing authorization for human therapeutic use anywhere, which is the trigger for WADA's S0 class of non-approved substances — prohibited at all times. Plainly: KPV is banned in tested sport, year-round, and a prescription does not change that. Check a specific compound with our prohibited-substance checker, and see the WADA 2026 prohibited list for peptides for how the categories work.

Where KPV sits on FDA's lists today

KPV is not in FDA's live Category 2 table. It sits in that page's second table — substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators"⁹. A withdrawn nomination is a procedural event, not a safety clearance, and it does not make KPV compoundable.

Which leaves a reader who came here for inflammation and healing with a practical problem: there is no legal route to KPV in the United States at all right now. If the underlying goal is recovery rather than KPV specifically, the honest alternative is the GH-releasing peptide route that licensed telehealth clinicians will actually prescribe — we compare those providers on price, clinical review and support on our ranked recovery-peptide provider board. Those are compounded products, not FDA-approved ones, and they are banned in tested sport too; the difference is that a prescriber and a pharmacy stand behind them.

The bottom line

A committee split 8–6–1 recommended KPV for a compounding list, for wound healing and inflammatory conditions, over the objection of FDA's reviewers and with one member saying openly that he did not know what he was voting on. Nothing is listed. Nothing is approved. No athletic indication was reviewed.

For the whole meeting, read what actually happened at the FDA peptide advisory vote. For the legal landscape, see are peptides legal?. For the science, see our KPV evidence review and the peptides for recovery and healing pillar.